Navigation Links
Studies reveal structure of EV71, a virus causing childhood illnesses
Date:3/2/2012

WEST LAFAYETTE, Ind. - Researchers have discovered critical new details about the structure of a virus that causes potentially fatal brain swelling and paralysis in children, pointing toward designs for antiviral drugs to treat the disease.

The virus, called enterovirus 71, causes hand, foot and mouth disease, and is common throughout the world. Although that disease usually is not fatal, the virus has been reported to cause encephalitis, a potentially fatal illness found primarily in the Asia-Pacific region.

Now, two research teams are reporting new findings about the structure of the virus. One of the teams, from Purdue University, has proposed a way to design antiviral drugs to treat the infection. Findings from that team are detailed in a paper appearing Thursday (March 1) in the online Express issue of the journal Science. Another team, led by researchers at Oxford University, will report its findings in a paper scheduled to appear Sunday (March 4) in the journal Nature Structural & Molecular Biology.

"Taken together, the findings in both papers are useful when you are trying to stop the virus from infecting host cells," said Michael G. Rossmann, Purdue's Hanley Distinguished Professor of Biological Sciences. "The common theme is that they both report for the first time on the structure of this virus, and this tells us how to design compounds to fight the infection."

Rossmann is co-author of a paper written by Purdue postdoctoral research associate Pavel Plevka; Purdue research scientist Rushika Perera; Richard J. Kuhn, a professor and head of Purdue's Department of Biological Sciences; and Jane Cardosa, a researcher at Sentinext Therapeutics in Malaysia.

Both teams used a technique called X-ray crystallography to determine the virus's precise structure, showing similarities to features on related enteroviruses, including poliovirus. However, a key feature is different in that a small molecule called a "pocket factor," located within a pocket of the protective shell of the virus, is partially exposed in EV71.

When the virus binds to a human cell, the pocket factor is squeezed out of its pocket resulting in the destabilization of the virus particle, which then disintegrates and releases its genetic material to infect the cell and replicate.

Researchers led by Rossmann have developed antiviral drugs for other enteroviruses such as rhinoviruses that cause the common cold. The drugs work by replacing the pocket factor with a molecule that binds more tightly than the real pocket factor.

This hinders infection in two ways: The drug molecule fills the pocket, making it difficult for a virus to bind to a human cell. Also, because the drug binds tightly to the pocket, it stabilizes the virus and keeps it from disintegrating and releasing its genetic material into the host cell.

However, in enterovirus 71 - or EV71 - a portion of the pocket factor sticks out of the pocket, exposing a hydrophilic tip, whereas the pocket factors in other related viruses are entirely enclosed in the pocket. In order to hinder EV71 infection, antiviral drugs must have a hydrophilic tip at one end to mimic the pocket factor.

"The major point of this paper is that it suggests how to design a drug to inhibit EV71 infection," Rossmann said.

Hand, foot and mouth disease, an infection most common among young children, sometimes arises in a daycare setting. Of the 427,278 cases of the disease recorded in mainland China between January and May 2010, 5,454 cases were classified as severe, with 260 deaths, according to the World Health Organization.

"Right now, there isn't much you can do for a child who contracts encephalitis," Kuhn said.

Future work will include research aimed at developing an antiviral drug for EV71. The research has been funded by the National Institutes of Health.


'/>"/>

Contact: Emil Venere
venere@purdue.edu
765-494-4709
Purdue University
Source:Eurekalert  

Related biology news :

1. Genetic studies of special mice could lead to rapid human health advances
2. Trading spaces: Biosecurity Research Institute to house Plum Islands pathogen studies
3. New tool offers unprecedented access for root studies
4. National experts from the John Theurer Cancer Center will present 31 studies at the 2011 ASH Meeting
5. UI engineers conduct residential soils study, one of few such US studies ever done
6. Brain, repair thyself: Studies highlight brains resiliency to damage
7. Combination therapy shows potent tumor growth inhibition in preclinical studies
8. Maryland climate plan passes key tests in UMD studies
9. CHEST 2011: Embargoed studies highlight new lung health research
10. CHEST 2011: Embargoed studies highlight new simulation education research
11. CHEST 2011: Embargoed studies highlight new sleep disorder research
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Studies reveal structure of EV71, a virus causing childhood illnesses
(Date:4/19/2016)... -- The new GEZE SecuLogic access control ... system solution for all door components. It can be ... interface with integration authorization management system, and thus fulfills ... dimensions of the access control and the optimum integration ... considerable freedom of design with regard to the doors. ...
(Date:4/14/2016)... 2016 BioCatch ™, the ... announced the appointment of Eyal Goldwerger as ... Goldwerger,s leadership appointment comes at a time of ... deployment of its platform at several of the world,s ... discerns unique cognitive and physiological factors, is a winner ...
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/23/2016)... WA (PRWEB) , ... June 23, 2016 , ... ... announces the release of its second eBook, “Clinical Trials Patient Recruitment and Retention ... recruitment and retention in this eBook by providing practical tips, tools, and strategies ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is pleased ... received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval of ... Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods perform ...
Breaking Biology Technology: